The country of origin of Norelgestromin and Ethinyl Estradiol Transdermal System (Patch)
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated July 20, 2026 , you requested a country of origin ruling on Norelgestromin and EthinylEstradiol Transdermal System, (Patch) 150/35 mcg per day.Norelgestromin and Ethinyl Estradiol Transdermal System, imported in 150/35 mcg per day, is acombination transdermal contraceptive system containing Norelgestromin (a progestin) and Ethinyl Estradiol(an estrogen), as the active ingredients.
It is indicated for the prevention of pregnancy in women with a bodymass index BMI < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.In your letter, you are requesting three different manufacturing scenarios for the Norelgestromin and EthinylEstradiol Patches. In your scenarios, the active pharmaceutical ingredients (APIs) Norelgestromin will bemanufactured in Argentina or Italy, and the Ethinyl Estradiol will be manufactured in Italy or India.
In allscenarios, the APIs (Norelgestromin and Ethinyl Estradiol) will be mixed with various inactive ingredients toproduce the final transdermal patches in dosage form in India.When determining the country of origin, the substantial transformation analysis is applicble. See, e.g.,aHeadquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether asubstantial transformation will occur is whether an article emerges from a process with a new name,character, or use different from that possessed by the article prior to processing. See exas Instruments Inc. v.T, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence.
See United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993).ational Hand Tool Corp. v. United StatesNIn determining whether a substantial transformation occurs in the manufacture of chemical products such aspharmaceuticals, CBP has consistently examined the complexity of the processing and whether the finalarticle retains the essential identity and character of the raw material.
To that end, CBP has generally heldthat the processing of pharmaceutical products from bulk form into measured doses does not result in asubstantial transformation of the product. See, e.g., HQ 561975, dated April 3, 2002; HQ 561544, dated May1, 2000; HQ 735146, dated November 15, 1993; HQ H267177, dated November 5, 2016; HQ H233356, dated December 26, 2012; and, HQ 561975, dated April 3, 2002.
However, where the processing from bulkform into measured doses involves the combination of two or more APIs, and the resulting combinationoffers additional medicinal benefits compared to taking each API alone, CBP has held that a substantialtransformation occurred. See, e.g., HQ 563207, dated June 1, 2005. I, we note that the two separate APIs are mixed to create a combination drug that offersn these casesadditional medicinal benefits compared to taking each API alone.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N363448).